Investors Urged to Join Capricor Therapeutics Securities Fraud Class Action Lawsuit

Call to Action for Capricor Investors

A significant deadline is approaching for investors in Capricor Therapeutics, Inc., a company traded under the ticker NASDAQ: CAPR. The Rosen Law Firm, an established global advocate for investor rights, has issued a crucial reminder for those who purchased Capricor securities between December 17, 2025 and July 26, 2026. These investors may have the opportunity to join a class action lawsuit that could yield compensation without incurring any out-of-pocket expenses due to a contingency fee agreement.

Understanding the Class Action

The Rosen Law Firm encourages anyone who bought Capricor securities during the specified class period to take action before the lead plaintiff deadline on September 28, 2026. Successfully joining this class action means you are represented without having to pay upfront fees, capitalizing on a unique arrangement whereby the lawyers receive a percentage of any settlement if the case is successful.

For those seeking to participate, joining the Capricor class action is straightforward. Interested individuals can visit the law firm's website or directly contact Phillip Kim, Esq. via toll-free number or email for more detailed information on the ongoing legal proceedings.

Case Background

According to the allegations set out in the class action lawsuit, Capricor made materially false and misleading statements regarding its operations, particularly concerning the development of Deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy (DMD). Key claims assert that the company failed to disclose significant changes to the pre-specified statistical analysis plan for its clinical data, a modification not agreed upon by the FDA before the pivotal resubmission of its Biologics License Application (BLA).

This miscommunication has raised serious concerns, suggesting that the FDA may not have found sufficient evidence to support regulatory approval for Deramiocel. As a direct consequence, the lawsuit asserts that investors were misled, resulting in substantial financial losses when the truth emerged, negatively impacting the share price.

The Right Legal Counsel Is Crucial

The onus is on investors to select competent representation in the complex landscape of securities class actions. The Rosen Law Firm stresses the importance of choosing counsel with proven expertise in these litigations. Unlike many firms that may only serve as intermediaries, the Rosen Law Firm has a distinguished track record, including a substantial securities class action settlement against a Chinese company and consistently being recognized at the top of its field in securing settlements for aggrieved investors.

Consistently ranking among the best in terms of recovery for investors, the firm has secured billions in settlements, including over $438 million in 2019 alone. Their founding partner, Laurence Rosen, has been recognized as a leading figure in the field, further bolstering their credibility in managing complex securities fraud cases.

What’s Next for Investors

As a reminder, there has yet to be any class certified. Until such formal recognition occurs, investors are not automatically represented and have the right to seek individual legal counsel of their choice. Additionally, investors may choose to remain inactive and retain the option of sharing in any potential recovery based on future developments in the case.

For ongoing updates, investors can follow the Rosen Law Firm on their social media platforms. Taking informed action is crucial, especially given the financial implications that could arise from the outcome of the lawsuit.

Ultimately, the Capricor class action lawsuit represents a key opportunity for affected investors to reclaim potential losses through collective legal action, making the upcoming deadline one that should not be overlooked.